55 research outputs found
Expression of cyclooxygenase-2 (COX-2) in tumour and stroma compartments in cervical cancer: clinical implications
This study aims at investigating the relationship between cyclooxygenase-2 expression in tumour vs stroma inflammatory compartment and its possible clinical role. The study included 99 stage IB-IV cervical cancer patients: immunostaining of tumour tissue sections was performed with rabbit antiserum against cyclooxygenase-2. CD3, CD4, CD8, CD25, Mast Cell Tryptase monoclonal antibodies were used to characterise stroma inflammatory cells in nine cervical tumours. An inverse relation was found between cyclooxygenase-2 levels (cyclooxygenase-2 IDV) of tumour vs stroma compartment (r=−0.44, P<0.0001). The percentage of cases showing high tumour/stromal cyclooxygenase-2 IDV ratio was significantly higher in patients who did not respond to treatment (93.3%) with respect to patients with partial (60.5%), and complete (43.7%) response (P= 0.009). Cases with a high tumour/stroma cyclooxygenase-2 IDV ratio had a shorter overall survival rate than cases with a low tumour/stroma cyclooxygenase-2 IDV (P<0.0001). In the multivariate analysis advanced stage and the status of tumour/stroma cyclooxygenase-2 IDV ratio retained an independent negative prognostic role. The proportion of CD3+, CD4+, and CD25+ cells was significantly lower in tumours with high tumour/stroma cyclooxygenase-2 IDV ratio, while a higher percentage of mast cells was detected in tumours showing high tumour/stroma cyclooxygenase-2 IDV ratio. Our study showed the usefulness of assessing cyclooxygenase-2 status both in tumour and stroma compartment in order to identify cervical cancer patients endowed with a very poor chance of response to neoadjuvant therapy and unfavourable prognosis
Morphological changes induced by epidermal growth factor and estradiol in CG-5 human breast cancer cellG line: a scanning electron microscopy study.
Type II estrogen binding sites in human peripheral blood mononuclear cells: variations during the menstrual cycle.
Parathyroid hormone-related peptide and parathyroid hormone-related peptide receptor type 1 expression in human lung adenocarcinoma
Clinical implications of glucocorticoid receptor studies in childhood acute lymphoblastic leukemia
Type II estrogen binding sites and 17beta-hydroxysteroid dehydrogenase activity in human peripheral blood mononuclear cells.
Interaction of tamoxifen with cytosolic and nuclear type II estrogen binding sites (type II EBS): correlation with growth inhibitory activity.
Synergistic antiproliferative activity of quercetin and cis- diamminedichloroplatinum on ovarian cancer cell growth.
Reply to the letter to the editors by Sakar MA: Quercetin not only inhibits the P-glycoprotein efflux activity but also inhibits CYP3A isozymes
Type II estrogen binding sites in a human lymphoblastoid cell line and growth inhibitory effect of estrogen, antiestrogen and bioflavonoids.
- …